Alcohol and GLP‑1 medications: risks and current research

Introduction

Ask your care team about alcohol if you take semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). Your other medicines, symptoms, and health history affect that decision. Alcohol can lower blood glucose, especially if you also take insulin or a sulfonylurea, and it can complicate treatment when you are eating little or losing fluids. 1 2 3

Consider symptoms and other medicines

The Wegovy and Zepbound instructions warn about severe digestive symptoms, kidney injury from dehydration, and pancreatitis, which is inflammation of the pancreas. They also warn about low blood sugar, with greater risk when combined with medicines such as insulin or sulfonylureas. These warnings do not establish a precise extra risk from a particular amount of alcohol. 2 3

Discuss drinking with your clinician if you have diabetes, a history of pancreatitis, liver disease, or difficulty maintaining food and fluid intake. Alcohol can make it harder to recognize or manage low blood glucose. Ask for a plan that accounts for your full medication list. 1

Trials suggest an effect on some drinking outcomes

Two trials tested semaglutide against placebo for alcohol use disorder:

• Injectable semaglutide, 2025: Researchers assigned 48 adults with alcohol use disorder by chance to semaglutide or placebo for nine weeks. The participants were not seeking treatment for their drinking. Doses were 0.25 mg weekly for four weeks, 0.5 mg for four weeks, and 1 mg for one week. Semaglutide reduced laboratory alcohol consumption and some drinking measures, including how much people drank on days when they drank alcohol. It did not reduce average drinks across all days or the number of days on which people drank. 4
• Oral semaglutide, 2026: Researchers assigned 50 adults seeking treatment for moderate to severe alcohol use disorder by chance to semaglutide or placebo. The semaglutide group took 3 mg daily for four weeks, then 7 mg daily for four weeks. Researchers found fewer heavy drinking days but no statistically clear improvement in cravings measured in the laboratory, the study’s main measure, or in drinks per day. 5

These small, short trials tested specific semaglutide doses as injections or tablets. They do not show that tirzepatide has the same effects or that GLP‑1 treatment makes alcohol harmless.

Discuss changes in cravings with your care team

Tell your clinician if you notice a change in how much you want to drink, even if you started medication for another reason. Bring the dates and doses from your treatment record. The trials above do not provide a schedule for changing your GLP‑1 dose to manage drinking; ask about established treatment options and support that fit your needs. 4 5 6

Seek care for concerning symptoms

Severe or persistent abdominal pain, especially with vomiting or pain extending to your back, needs prompt assessment. Contact your clinician if vomiting or diarrhea prevents you from drinking enough. Confusion, fainting, or other severe symptoms require urgent care. 1 2 3

If you struggle to control drinking, ask about established alcohol-use-disorder treatments. People who may be physically dependent should seek medical guidance before stopping because withdrawal can be dangerous. 6

Keep notes with Shotsy

Use Shotsy’s notes and symptom log to record changes around drinking and dose dates. Share concerns with your clinician; the app cannot diagnose an interaction or treat alcohol use disorder.

Conclusion

Deciding whether to drink while taking a GLP‑1 starts with your health and how you feel on treatment. Ask your clinician whether alcohol is appropriate for you, what limits to follow, and whether your other medicines require extra precautions. If drinking makes it harder to eat, stay hydrated, or manage symptoms, discuss those changes before drinking again.